Funding for this research was provided by:
Canadian Consortium for Neurodegeneration in Aging (Fellowship Award)
Alzheimer's Drug Discovery Foundation (GC-201808-2016354)
Weston Brain Institute (CT190002)
Accepted: 2 December 2021
First Online: 23 December 2021
: The authors report research support from the Alzheimer’s Drug Discovery Foundation (grant no. GC-201808-2016354), Weston Foundation (grant no. CT190002), and the Canadian Consortium for Neurodegeneration in Aging (CCNA) to NH and KL, and through a CCNA fellowship to ST. The funders had no role in the design or conduct of the study, nor in the writing or approval for publication of the manuscript.
: AD consulted on unrelated projects with Canabo Medical, a subsidiary of Aleafia Health, a publicly traded company, which overlapped with the period of data collection. AD has no current financial relationship with either Aleafia Health or with Canabo Medical, and did not receive financial or other considerations for this article. The rest of the authors declare no competing interest.
: The study was approved by the Sunnybrook Research Ethics Board.
: All participants consented to participating in the data collection and sharing anonymized data for research purposes.
: All authors approved the final version for publication.
: The data that support the findings of this study were obtained from Aleafia Health and are not publicly available. Further analyses of data reported in this study are available from the authors upon reasonable request and with permission of Aleafia Health.
: STATA 15.1 was used to extract data with in-built commands, which can be made available on reasonable request to the authors.
: ST, KL, AD, and NH contributed to the conception and design of the work. AD analyzed the data, ST, KL, AD, and NH interpreted the data. The first draft of the manuscript was written by ST and RW. ST, KL, RW, AL, AD, and NH critically reviewed the manuscript.
Free to read: This content has been made available to all.